Since the 1950s, methotrexate (MTX) has been an effective treatment for patients with psoriasis. Although initially used as an antineoplastic drug, in recent history, MTX has become useful for the treatment of a broad range of non-neoplastic proliferative dermatoses, particularly psoriasis. The guidelines for use of MTX in psoriasis patients provide a unique perspective of the discoveries and new information that we have learned about MTX over the years. In this historical review, we analyze the development of MTX and the circumstances that led to its use as an effective treatment for psoriasis.
FarberS., DiamondL.K.Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med.1948; 238: 787–93.
2.
GubnerR.Effect of “aminopterin” on epithelial tissues. Arch Dermatol.1983; 119: 513–24.
3.
GubnerR.S.Introduction of antifolics in psoriasis. A twenty-five year retrospect of antineoplastic agents in nonmalignant disease. Cutis1979; 23: 425–8.
4.
KuhnA., RulandV., PatsinakidisN.Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol.2010; 28: S138–44.
5.
ShenS., O'BrienT., YapL.M.The use of methotrexate in dermatology: a review. Australas J Dermatol.2012; 53: 1–18.
6.
MenterM.A., KruegerG.C., FeldmanS.R.Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol.2003; 49: S39–43.
7.
KooJ.Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin1996; 14: 485–96.
8.
KurdS.K., GelfandJ.M.The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol.2009; 60: 218–24.
9.
SternR.S., NijstenT., FeldmanS.R.Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc.2004; 9: 136–9.
10.
SchönM.P., BoehnckeW-HPsoriasis. N Engl J Med2005; 352: 1899–1912.
11.
YamauchiP.S., RizkD., KormeiliT.Current systemic therapies for psoriasis: where are we now?J Am Acad Dermatol.2003; 49: S66–77.
12.
LebwohlM.A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol.2005; 53(1 suppl): S59–69.
13.
EdmundsonW.F., GuyW.B.Treatment of psoriasis with folic acid antagonists. AMA Arch Derm.1958; 78: 200–3.
14.
BenedekT.G.Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-α. Clin Exp Rheumatol.2010; 28: S3–8.
15.
Van ScottE.J., AuerbachR., WeinsteinG.D.Parenteral methotrexate in psoriasis. Arch Dermatol.1964; 89: 550–6.
16.
CronsteinB.N.The mechanism of action of methotrexate. Rheum Dis Clin North Am.1997; 23: 739–55.
17.
WeinsteinG.D., GoldfadenG., FrostP.Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol.1971; 104: 236–43.
18.
ChanE.S.L., CronsteinB.N.Methotrexate–how does it really work?Nat Rev Rheumatol.2010; 6: 175–8.
19.
GubnerR.Effect of aminopterin on epithelial tissues. AMA Arch Derm Syphilol.1951; 64: 688–99.
20.
CronsteinB.N., NaimeD., OstadE.The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest.1993; 92: 2675–82.
21.
StampL.K., HazlettJ., RobertsR.L.Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther.2012; 14: R138.
22.
BraunJ.Optimal administration and dosage of methotrexate. Clin Exp Rheumatol.2010; 28: S46–51.
23.
HryniukW.M., FischerG.A., BertinoJ.R.S-phase cells of rapidly growing and resting populations: differences in response to methotrexate. Mol Pharmacol.1969; 5: 557–64.
HeinleR.W., WelchA.D.Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. J Clin Invest.1948; 27: 539.
26.
BergstresserP.R., SchreiberS.H., WeinsteinG.D.Systemic chemotherapy for psoriasis: a national survey. Arch Dermatol.1976; 112: 977–81.
27.
GoldinA., VendittiJ.M., HumphreysS.R.A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. J Natl Cancer Inst.1955; 15: 1657–64.
28.
HunterG.A., TurnerA.N.Methotrexate in the treatment of psoriasis: a controlled clinical trial. Aust J Dermatol.1963; 7: 91–2.
29.
RoenigkH.H.Jr., HaserickJ.R., CurtisG.H.Methotrexate for psoriasis: a preliminary report. Cleve Clin Q.1965; 32: 211–5.
30.
Van ScottE.J.Psoriasis: practical therapeutic perspectives. Ration Drug Ther.1973; 7: 1–5.
31.
ReesR.B., BennettJ.H.Methotrexate vs. aminopterin for psoriasis. Arch Dermatol.1961; 83: 970–2.
32.
StrakoschE.A.A study of the folic acid antagonists in the treatment of psoriasis (aminopterin vs. methotrexate vs. aminopterin and a corticosteroid). Dermatologica.1963; 126: 259–67.
33.
ReesR.B., BennettJ.H.Psoriasis–chemotherapy with aminopterin and methotrexate. Skin (Los Angeles).1962; 1: 381–2.
34.
BlackR.L., O'BrienW.M., Van ScottE.J.Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA.1964; 189: 743–7.
35.
RyanT.J., BakerH.Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis: evaluation and prognosis based on the study of 104 cases. Br J Dermatol.1969; 81: 134–45.
36.
RoenigkH.H.Psoriasis: Proceedings of the International Symposium.FarberE.M., CoxA.J., eds. Stanford University Press (Stanford, CA); 1971.
37.
WeinsteinG.D.Methotrexate. Ann Intern Med.1977; 86: 199–204.
38.
RoenigkH.H.Jr., MaibachH.I., WeinsteinG.D.Use of methotrexate in psoriasis. Arch Dermatol.1972; 105: 363–5.
39.
KalbR.E., StroberB., WeinsteinG.Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol.2009; 60: 824–37.
RoenigkH.H.Jr., AuerbachR., MaibachH.I.Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol.1988; 19(1 pt 1): 145–56.
42.
RoenigkH.H.Jr., AuerbachR., MaibachH.Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol.1998; 38: 478–85.
43.
DuhraP.Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol.1993; 28: 466–9.
44.
WeinsteinG.D., CoxJ.W., SuringaD.W.Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Dermatol.1970; 102: 613–8.
45.
ColskyJ., GreenspanE.M., WarrenT.N.Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. AMA Arch Pathol.1955; 59: 198–206.
46.
O'RourkeR.A., EckertG.E.Methotrexate-induced hepatic injury in an adult: a case report. Arch Intern Med.1964; 113: 191–4.
47.
Whiting-O'KeefeQ.E., FyeK.H., SackK.D.Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med.1991; 90: 711–6.
48.
BannwarthB., LabatL., MorideY.Methotrexate in rheumatoid arthritis: an update. Drugs.1994; 47: 25–50.
49.
BarkerJ., HornE.J., LebwohlM.Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol.2011; 25: 758–64.
50.
BerendsM.A.M., van OijenM.G.H., SnoekJ.Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol.2007; 143: 1515–9.
51.
RosenbergP., UrwitzH., JohannessonA.Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol.2007; 46: 1111–8.
52.
HsuS., PappK.A., LebwohlM.G.Consensus guidelines for the management of plaque psoriasis. Arch Dermatol.2012; 148: 95–102.
53.
KremerJ.M., AlarcónG.S., LightfootR.W.Jr.Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum.1994; 37: 316–28.
54.
PeckhamP.E., WeinsteinG.D., McCulloughJ.L.The treatment of severe psoriasis: a national survey. Arch Dermatol.1987; 123: 1303–7.
55.
SaporitoF.C., MenterM.A.Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol.2004; 50: 301–9.
56.
LiemW.H., McCulloughJ.L., WeinsteinG.D.Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis.1995; 55: 306–10.
57.
AlbrechtK., Müller-LadnerU.Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol.2010; 28: S95–101.
58.
SalliotC., van der HeijdeD.Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis.2009; 68: 1100–4.
59.
MorganS.L., BaggottJ.E.Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol.2010; 28: S102–9.
60.
AuerbachR., OrentreichN., BergerR.Diagnosis: psoriasis and psoriatic arthropathy treated with methotrexate administered intravenously. Arch Dermatol.1964; 90: 115–6.
61.
WeinsteinG.D., FrostP.Methotrexate for psoriasis: a new therapeutic schedule. Arch Dermatol.1971; 103: 33–8.
62.
WeinsteinG.D., FrostP.Cell proliferation kinetics in benign and malignant skin diseases in humans. Natl Cancer Inst Monogr.1969; 30: 225–46.
KuijpersA.L., van de KerkhofP.C.Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol.2000; 1: 27–39.
68.
van RoonE.N., van de LaarMAFJMethotrexate bioavailability. Clin Exp Rheumatol.2010; 28: S27–32.
69.
GodfreyC., SweeneyK., MillerK.The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol.1998; 46: 369–76.
70.
SwierkotJ., SzechińskiJ.Methotrexate in rheumatoid arthritis. Pharmacol Rep.2006; 58: 473–92.
71.
OgueyD., KöllikerF., GerberN.J.Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum.1992; 35: 611–4.
72.
WolvertonS.E.Comprehensive Dermatologic Drug Therapy. 2nd ed. Saunders Elsevier (Philadelphia); 2007.
73.
BrooksP.J., SpruillW.J., ParishR.C.Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum.1990; 33: 91–4.
ZackheimH.S.Subcutaneous administration of methotrexate. J Am Acad Dermatol.1992; 26: 1008.
76.
FelsonD.T., AndersonJ.J., BoersM.American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum.1995; 38: 727–35.
77.
BraunJ., KästnerP., FlaxenbergP.Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum.2008; 58: 73–81.
78.
SauratJ-H, StinglG., DubertretL.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol.2008; 158: 558–66.
79.
LangleyR.G.Effective and sustainable biologic treatment of psoriasis what can we learn from new clinical data?J Eur Acad Dermatol Venereol.2012; 26(suppl 2): 21–9.
80.
HeydendaelV.M.R., SpulsP.I., OpmeerB.C.Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med.2003; 349: 658–65.
81.
ThaçiD., OrtonneJ-P, ChimentiS.A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/β methasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol.2010; 163: 402–11.
82.
MenterA., GordonK.B., LeonardiC.L.Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol.2010; 63: 448–56.
83.
LebwohlM., MenterA., KooJ.Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol.2004; 50: 416–30.
84.
MainiR., St ClairE.W., BreedveldF.Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet.1999; 354: 1932–9.
85.
MainiR.N., BreedveldF.C., KaldenJ.R.Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum.1998; 41: 1552–63.
86.
Ben-HorinS., WatermanM., KopylovU.Addition of an immunomodulator to infliximab therapy eliminates anti-drug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. In press.
PuigL.Treatment of severe psoriasis. J Eur Acad Dermatol Venereol.2012; 26(suppl 5): 17–8.
89.
MieleE., MarkowitzJ.E., MamulaP.Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr.2004; 38: 502–8.
90.
ColeP.D., ZebalaJ.A., KamenB.A.Antimetabolites: a new perspective. Drug Discov Today Ther Strateg.2005; 2: 337–42.
